UNIVERSITE DE MONTPELLIER 1 Patent applications |
Patent application number | Title | Published |
20150307887 | FLT3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OR THE PREVENTION OF PAIN DISORDERS - The present invention relates to FLT3 receptor antagonists or inhibitors of FLT3 receptor gene expression for the treatment or the prevention of pain disorders. | 10-29-2015 |
20140371092 | METHODS FOR ASSESSING ENDOMETRIAL RECEPTIVITY OF A PATIENT AFTER CONTROLLED OVARIAN HYPERSTIMULATION - The present invention relates to methods and kits for assessing the endometrial receptivity of a patient after controlled ovarian hyperstimulation. More particularly, the invention relates to a method for assessing the endometrial receptivity of a patient after controlled ovarian hyperstimulation, comprising a step consisting of measuring the expression level of at least one gene selected from fifteen genes in an endometrial biopsy sample obtained from said patient wherein said genes are FGFBP1, MUC20, TM-PRSS3, PRUNE2, HES2, MGST1, ERRFI1, EDN1, SLC17A7, MET, CPT1B, DCDC2, LRRC39, IL18RAP, and FOXP1. | 12-18-2014 |
20140302041 | ANTI-AXL ANTIBODIES AND USES THEREOF - The present invention relates to anti-Axl antibodies and uses thereof in diagnostic and therapeutic methods. More particularly, the present invention relates to a monoclonal antibody having specificity for Axl comprising an heavy chain variable region comprising SEQ ID NO:2 in the H-CDR1 region, SEQ ID NO:3 in the H-CDR2 region and SEQ ID NO:4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 6 in the L-CDR1 region, SEQ ID NO:7 in the L-CDR2 region and SEQ ID NO:8 in the L-CDR3 region. Said monoclonal antibody binds to the extracellular domain of Axl via, SEQ ID NO:9, SEQ ID NO: 10 and SEQ ID NO: 11. | 10-09-2014 |
20140134632 | METHODS FOR DETERMINING DEVELOPMENTAL STAGE OF HUMAN CUMULUS CELLS - The present invention relates generally to the fields of reproductive medicine. More specifically, the present invention relates to a method determining the developmental stage of human cumulus cells issues from MII oocyte. | 05-15-2014 |
20140112931 | ANTI-HUMAN HER3 ANTIBODIES AND USES THEREOF - The present invention provides for isolated anti-human-HER3 antibodies or fragments thereof. More particularly the present invention provides an isolated monoclonal antibody that specifically binds to the extracellular domain of HER-3 and competes for binding to the extracellular domain of human HER-3 with the antibody produced obtainable from hybridoma deposited as CNCM-I-4486. The antibodies described in the present invention are useful for the treatment of cancer. | 04-24-2014 |
20130316360 | METHODS FOR SELECTING COMPETENT OOCYTES AND COMPETENT EMBRYOS WITH HIGH POTENTIAL FOR PREGNANCY OUTCOME - The present invention relates to a method for selecting a competent oocyte or a competent embryo by determining the expression level of specific microRNA species in a body fluid or in cumulus cells. | 11-28-2013 |
20130288979 | Inhibitors of Apoptosis and Uses Thereof - The invention relates to fragments of the DAXX and FADD proteins that inhibit cell apoptosis, in particular cell apoptosis mediated by the Fas receptor. The invention also relates to derivatives of said anti-apoptotic fragments, conjugates comprising said fragments, pharmaceutical compositions comprising said fragments, and to the medical applications of said fragments, derivatives, conjugates, and pharmaceutical compositions thereof in the treatment or prevention of diseases and conditions associated with apoptosis. | 10-31-2013 |
20120093795 | COMPOUNDS TARGETING THE CATION-INDEPENDENT MANNOSE 6-PHOSPHATE RECEPTOR - The invention relates to conjugates of products of interest and of compounds targeting the cation-independent mannose 6-phosphate receptor with a high affinity. The invention also relates to their applications, for instance in enzyme replacement therapies. | 04-19-2012 |
20110256090 | Method for Identifying Genes Involved in Trail-Induced Apoptosis and Therapeutic Applications Thereof - The invention relates to methods for identifying genes involved in TRAIL-induced apoptosis, to inhibitors of the expression of genes inducing resistance of cells to TRAIL-induced apoptosis and to activators of the expression of a gene sensitizing cells to TRAIL-induced apoptosis. The invention also relates to methods for sensitizing cells to TRAIL-induced apoptosis, methods for treating hyperproliferative diseases, methods for determining the responsiveness of a subject suffering from a hyperproliferative disease to TRAIL, to pharmaceutical compositions comprising products capable of sensitizing cells to TRAIL-induced apoptosis, and to methods for determining the prognosis of a subject suffering from a hyperproliferative disease. | 10-20-2011 |
20110038844 | COMPOSITIONS FOR TREATING AN ARTHRITIC CONDITION - The present invention relates to compositions comprising human Tr1 cells directed to a joint-associated antigen and methods for treating an arthritic condition. | 02-17-2011 |
20100260848 | SYSTEM FOR CONTROLLED RELEASE OF AN ACTIVE PRINCIPLE AND METHOD FOR PREPARATION - A system for controlled release of an active principle, includes at least (a) a degradable polymer matrix which produces acid compounds and (b) at least one acid-sensitive complex of an active principle having at least one electrostatic charge and a complexing polyelectrolyte partner of opposite charge which complexes with the active principle. A method for preparation of such a system is described. The release of the active principle (7P) is prolonged over 18 days (ternary system PMLA/7P/PLAGA) in comparison to binary systems (7P/PLAGA) and (PMLA/7P). | 10-14-2010 |
20100240084 | USE OF THE PROTIEN MABA (FABG1) OF MYCOBACTERIUM TUBERCULOSIS FOR DESIGNING AND SCREENING ANTIBIOTICS - The protein MabA, also named protein FabG1, which is recombinant in a purified form, or the recombinant proteins derived from the protein MabA by mutation of at least one amino acid. The uses of proteins MabA, or recombinant proteins derived from protein MabA by mutation of at lease one amino acid, proteins and to the crystalloghraphis co-ordinates thereof, in terms of the implementation of methods for designing and screening ligands of these proteins, and advantageously, ligands inhibiting the enzymatic activity of these proteins. | 09-23-2010 |
20100209426 | INHIBITORS OF PROGASTRIN-INDUCED REPRESSION OF ICAT FOR TREATING AND/OR PREVENTING COLORECTAL CANCER, ADENOMATOUS POLYPOSIS OR METASTASIS DISPLAYING PROGASTRIN-SECRETING CELLS AND CELLS IN WHICH THE BETA-CATENIN/TCF-MEDIATED TRANSCRIPTIONAL PATHWAY IS CONSTITUTIVELY ACTIVE - The present invention relates to inhibitors of progastrin induced repression of ICAT for treating and/or preventing colorectal cancer, adenomatous polyposis or metastasis displaying progastrin-secreting cells and cells in which the beta-catenin/Tcf-4-mediated transcriptional pathway is constitutively active. | 08-19-2010 |
20090291116 | Biocompatible and Biodegradable Porous Matrix in Particular Useful for Tissue Reconstruction - The invention mainly concerns a biocompatible and biodegradable porous matrix, characterized in that it is made of a three-block sequenced copolymer of formula (I): X G Y (I), wherein: G is a non-hydroxylated hydrophilic linear block, and X and Y represent respectively a hydrophobic linear polyester block. The invention further concerns the use of said matrix for coating tissue reconstruction after loss of substance or bioactive dressings. | 11-26-2009 |